Vernalis (VER)


VER Share PerformanceMore

52 week high49.750 18/07/16
52 week low16.000 18/05/17
52 week change -27.195 (-60.44%)
4 week volume11,366,387 29/04/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Total Voting Rights

RNS Number: 5935D Vernalis PLC 28 April 2017 TOTAL VOTING RIGHTS VERNALIS PLC (the "Company") 28 April 2017 Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,386,480 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury. The total numbe...

Vernalis and Servier announce three milestones

Vernalis and Servier announce the achievement of two research milestones and one clinical milestone in their oncology dr...

Servier and Vernalis announce 3 milestones

RNS Number: 3244D Vernalis PLC 26 April 2017 Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration Two research milestones and one clinical milestone, triggering a total payment of 2 million to Vernalis 26 April 2017 - Servier and Vernalis plc are pleased to announce the achievement of two research milesto...

Broker Forecast - Panmure Gordon issues a broker note on Vernalis PLC

Panmure Gordon today downgrades its investment rating on Vernalis PLC (LON:VER) to hold (from buy) and left its pri...

Broker Forecast - Stifel issues a broker note on Vernalis PLC

Stifel today reaffirms its hold investment rating on Vernalis PLC (LON:VER) and cut its price target to 24p (from 29p).

FTSE struggles as dominant blue-chips fall

Weakness in pharmaceutical stocks AstraZeneca (AZN) and Hikma (HIK), as well as consumer goods giants Reckitt Benck...

FTSE ahead as miners up with industrial metals prices

London shares are making minor gains in early deals with multi-commodity miners benefiting from rises in industrial m...

Vernalis to resubmit NDA to US FDA for drug CCP-07

Vernalis said a complete response letter (CRL) from the US FDA did not raise any concerns with the formulation or pharm...

Fundamental DataMore

Dividend yield0 %

Equity Research (VER)

edison investment research
Vernalis plc
FDA has issued a complete response letter (CRL) to Vernalis’ CCP-07 NDA following its 20 April PDUFA date, outlining questions that need to be addressed in an NDA resubmission for potential FDA...
edison investment research
Vernalis plc
Investment into addressing barriers to higher Tuzistra XR prescribing is starting to translate into higher prescription (Rx) rates. Mid-way through the second season post launch, both Rx and sales...
edison investment research
Vernalis plc
FDA acceptance of the CCP-08 NDA (setting a 4 August 2017 PDUFA date) advances Vernalis towards its goal of building a speciality US franchise of extended release (ER) prescription-only (Rx) cough...

Latest discussion posts More

  • Perfect short this one !

    Just need to time the close now ! Lurking on these beautiful trending stocks you can bet is where you can find me ! Its all I look out for 24/7 !! Just need the time to ...
  • Now Woody's Buying

    Just me and him then, anyone else? M
    sound money
  • More Director Buying.

    Wow these guys really believe this is a winner. Glad I bought in last week. M
    sound money

Users' HoldingsMore

Users who hold Vernalis also hold..

Codes & Symbols